Biocon’s Biosimilar Ambitions Get A Boost With European Site Approval
Leading Indian biotech firm Biocon has got the green light for a biosimilar manufacturing facility from Europe’s drug regulator, paving the way for the company’s growing biosimilars portfolio to gain greater European market access.
You may also be interested in...
Biocon has received European regulatory clearance for its new Malaysian insulin plant and also said it is open to private-equity investment proposals for its fast-growing biologics division ahead of a planned IPO.
Biocon rang in a strong fourth quarter amid signs of a build-up in efforts towards supporting the “independent functioning” of its biosimilars business under subsidiary Biocon Biologics.
Biocon rang in a strong Q3, buoyed by the momentum in its biologics business. The firm appears undeterred by suggestions that the US biosimilars market may be less attractive than initially anticipated.